Related Experiment Video

Updated: Jun 2, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

Impact of polymorphisms in the renin-angiotensin-aldosterone system on hypertrophic cardiomyopathy

Esteban Orenes-Piñero1, Diana Hernández-Romero, Eva Jover

  • 1Department of Cardiology, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain. eorenes@um.es

Journal of the Renin-Angiotensin-Aldosterone System : JRAAS
|April 22, 2011
PubMed

Insights

Hypertrophic cardiomyopathy (HCM) is a genetic heart condition with varied symptoms. This review explores how renin-angiotensin-aldosterone system (RAAS) gene variations may influence HCM severity and progression.

Area of Science:

  • Cardiology
  • Genetics
  • Molecular Biology

Background:

  • Hypertrophic cardiomyopathy (HCM) is an autosomal dominant heart disease marked by left ventricular hypertrophy.
  • HCM involves cardiomyocyte hypertrophy, myofibrillar disarray, and fibrosis, often due to sarcomere protein gene mutations.
  • Phenotypic variability in HCM is high, even within families sharing the same mutation, suggesting influence from other genetic factors.

Purpose of the Study:

  • To review the role of renin-angiotensin-aldosterone system (RAAS) polymorphisms in modifying the phenotype of hypertrophic cardiomyopathy.
  • To investigate how genetic variants in the RAAS pathway may influence left ventricular hypertrophy in HCM patients.

Main Methods:

  • Literature review of studies investigating RAAS polymorphisms in hypertrophic cardiomyopathy.
  • Analysis of genetic association studies linking RAAS variants to HCM clinical presentation and severity.

Main Results:

  • Polymorphisms in RAAS genes are hypothesized to act as disease modifiers in HCM.
  • These genetic variants may alter RAAS activation status, contributing to left ventricular hypertrophy through various pathways.
  • Evidence suggests a potential link between specific RAAS polymorphisms and HCM phenotype variability.

Conclusions:

  • The renin-angiotensin-aldosterone system (RAAS) is a significant area of interest for understanding HCM genetic modifiers.
  • Further research into RAAS polymorphisms could reveal novel therapeutic targets for managing HCM.
  • Understanding these genetic influences is crucial for personalized medicine approaches in hypertrophic cardiomyopathy treatment.

More Related Videos

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix10:21

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix

Published on: June 14, 2016

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level06:02

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level

Published on: November 2, 2020

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...